English

Revolution Medicines, Inc.

EDGAR

RVMD Current report (8-K) · filed 2026-10-13

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-138 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -557436000 USD Source
Operating Cash Flow: -419146000 USD Source

Free cash flow

-140 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -557436000 USD Source
Operating Cash Flow: -419146000 USD Source
Capital Expenditure: 10308000 USD Source
Capital Expenditure: 9086000 USD Source

Cash and cash equivalents: 815 million USD 2026-06-30 Source
Exact value

815435000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 214 million shares 2026-06-30 Source
Exact value

214242688 shares

Reported share-count change

14.63% · 27.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

186901268 shares · 2025-06-30· Source
214242688 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Revenue: 0 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 0 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 0 USD · 2024-07-01 – 2024-09-30 Source
Revenue: 0 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 0 USD · 2024-01-01 – 2024-09-30 Source

Net income

-1.77 billion USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -305206000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -1131301000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -766409000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -453816000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -644371000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-1.22 billion USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -623503000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -416192000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -897741000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -623503000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -354165000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -741484000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -354165000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

9.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 14065000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 10716000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 15990000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 14065000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1538000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 3824000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1538000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-1.23 billion USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -623503000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -416192000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -897741000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -623503000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -354165000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -741484000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -354165000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 14065000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 10716000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 15990000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 14065000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1538000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 3824000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1538000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2025-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Revolution Medicines, Inc. · 2025-12-31 Revolution Medicines, Inc. (edgar:1628171) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#1634430 Filing: 000119312526071563 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#1636070 Filing: 000119312526071563
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 531.21 million

Prior period

−USD 600.09 million

2024-01-01 – 2024-12-31
Current period

−USD 1.13 billion

2025-01-01 – 2025-12-31

Exact inputs and evidence

-1131301000 − -600093000 = -531208000 USD

-600093000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-1131301000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Revolution Medicines, Inc. · 2025-12-31 Revolution Medicines, Inc. (edgar:1628171) Year-over-year change in Net income: -531208000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -1131301000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2085793 Filing: 000119312526071563 Input fundies:NetIncome: -600093000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#1988974 Filing: 000119312526071563
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 340.31 million

Prior period

−USD 557.44 million

2024-01-01 – 2024-12-31
Current period

−USD 897.74 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-897741000 − -557436000 = -340305000 USD

-557436000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-897741000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Revolution Medicines, Inc. · 2025-12-31 Revolution Medicines, Inc. (edgar:1628171) Year-over-year change in Operating cash flow: -340305000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -897741000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2225116 Filing: 000119312526071563 Input fundies:OperatingCashFlow: -557436000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2227000 Filing: 000119312526071563
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+55.1%

Prior period

USD 10.31 million

2024-01-01 – 2024-12-31
Current period

USD 15.99 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

15990000 − 10308000 = 5682000 USD

10308000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
15990000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Revolution Medicines, Inc. · 2025-12-31 Revolution Medicines, Inc. (edgar:1628171) Year-over-year change in Capital expenditure: 5682000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 15990000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2251376 Filing: 000119312526071563 Input fundies:CapitalExpenditure: 10308000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2253250 Filing: 000119312526071563
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 1.18 billion
Operating income −USD 1.18 billion
Tax, interest and other Derived −USD 51.07 million
Net income −USD 1.13 billion

Cash

Operating cash flow −USD 897.74 million
Capital expenditure USD 15.99 million
Free cash flow Derived −USD 913.73 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Operating loss: operating costs were 300% of revenue.
2019 Operating loss: operating costs were 208% of revenue.
2020 Operating loss: operating costs were 358% of revenue.
2021 Operating loss: operating costs were 740% of revenue.
2022 Operating loss: operating costs were 830% of revenue.
2023 Operating loss: operating costs were 4,307% of revenue.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	20165000	60494000 Derived	-40329000	1460000 Derived	-41789000	-286000 Derived	Source 2018-01-01 – 2018-12-31: 20165000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -40329000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -41789000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 1213000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1499000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	50041000	104161000 Derived	-54120000	-6456000 Derived	-47664000	-52205000 Derived	Source 2019-01-01 – 2019-12-31: 50041000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -54120000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -47664000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -49616000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2589000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	42983000	153680000 Derived	-110697000	-2538000 Derived	-108159000	-102997000 Derived	Source 2020-01-01 – 2020-12-31: 42983000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -110697000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -108159000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -100064000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 2933000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	29390000	217398000 Derived	-188008000	-917000 Derived	-187091000	-153708000 Derived	Source 2021-01-01 – 2021-12-31: 29390000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -188008000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -187091000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -147180000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 6528000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	35380000	293659000 Derived	-258279000	-9574000 Derived	-248705000	-235217000 Derived	Source 2022-01-01 – 2022-12-31: 35380000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -258279000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -248705000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -224401000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 10816000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	11580000	498765000 Derived	-487185000	-50818000 Derived	-436367000	-358301000 Derived	Source 2023-01-01 – 2023-12-31: 11580000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -487185000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -436367000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -350572000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 7729000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	689524000 Derived	-689524000	-89431000 Derived	-600093000	-567744000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -689524000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -600093000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -557436000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 10308000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	1182369000 Derived	-1182369000	-51068000 Derived	-1131301000	-913731000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -1182369000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -1131301000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -897741000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 15990000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	20165000	Revenue: 20165000 Open source
20192019-12-31	Revenue	50041000	Revenue: 50041000 Open source
20202020-12-31	Revenue	42983000	Revenue: 42983000 Open source
20212021-12-31	Revenue	29390000	Revenue: 29390000 Open source
20222022-12-31	Revenue	35380000	Revenue: 35380000 Open source
20232023-12-31	Revenue	11580000	Revenue: 11580000 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 20165000 Open source
20192019-12-31	Year over year	148.2%	Revenue: 50041000 Open source Revenue: 20165000 Open source
20202020-12-31	Year over year	-14.1%	Revenue: 42983000 Open source Revenue: 50041000 Open source
20212021-12-31	Year over year	-31.6%	Revenue: 29390000 Open source Revenue: 42983000 Open source
20222022-12-31	Year over year	20.4%	Revenue: 35380000 Open source Revenue: 29390000 Open source
20232023-12-31	Year over year	-67.3%	Revenue: 11580000 Open source Revenue: 35380000 Open source
20242024-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 11580000 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,207.1% 2023

Net margin -3,768.3% 2023

Free cash flow margin -3,094.1% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	-200%	Operating Income: -40329000 Open source Revenue: 20165000 Open source
20192019-12-31	Operating margin	-108.2%	Operating Income: -54120000 Open source Revenue: 50041000 Open source
20202020-12-31	Operating margin	-257.5%	Operating Income: -110697000 Open source Revenue: 42983000 Open source
20212021-12-31	Operating margin	-639.7%	Operating Income: -188008000 Open source Revenue: 29390000 Open source
20222022-12-31	Operating margin	-730%	Operating Income: -258279000 Open source Revenue: 35380000 Open source
20232023-12-31	Operating margin	-4,207.1%	Operating Income: -487185000 Open source Revenue: 11580000 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -689524000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -1182369000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	-207.2%	Net Income: -41789000 Open source Revenue: 20165000 Open source
20192019-12-31	Net margin	-95.2%	Net Income: -47664000 Open source Revenue: 50041000 Open source
20202020-12-31	Net margin	-251.6%	Net Income: -108159000 Open source Revenue: 42983000 Open source
20212021-12-31	Net margin	-636.6%	Net Income: -187091000 Open source Revenue: 29390000 Open source
20222022-12-31	Net margin	-703%	Net Income: -248705000 Open source Revenue: 35380000 Open source
20232023-12-31	Net margin	-3,768.3%	Net Income: -436367000 Open source Revenue: 11580000 Open source
20242024-12-31	Net margin	Not reported	Net Income: -600093000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	Not reported	Net Income: -1131301000 Open source Revenue: 0 Open source
20182018-12-31	Free cash flow margin	-1.4%	Revenue: 20165000 Open source Operating Cash Flow: 1213000 Open source Capital Expenditure: 1499000 Open source
20192019-12-31	Free cash flow margin	-104.3%	Revenue: 50041000 Open source Operating Cash Flow: -49616000 Open source Capital Expenditure: 2589000 Open source
20202020-12-31	Free cash flow margin	-239.6%	Revenue: 42983000 Open source Operating Cash Flow: -100064000 Open source Capital Expenditure: 2933000 Open source
20212021-12-31	Free cash flow margin	-523%	Revenue: 29390000 Open source Operating Cash Flow: -147180000 Open source Capital Expenditure: 6528000 Open source
20222022-12-31	Free cash flow margin	-664.8%	Revenue: 35380000 Open source Operating Cash Flow: -224401000 Open source Capital Expenditure: 10816000 Open source
20232023-12-31	Free cash flow margin	-3,094.1%	Revenue: 11580000 Open source Operating Cash Flow: -350572000 Open source Capital Expenditure: 7729000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -557436000 Open source Capital Expenditure: 10308000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -897741000 Open source Capital Expenditure: 15990000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -897.7M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	1213000	Operating Cash Flow: 1213000 Open source
20192019-12-31	Operating cash flow	-49616000	Operating Cash Flow: -49616000 Open source
20202020-12-31	Operating cash flow	-100064000	Operating Cash Flow: -100064000 Open source
20212021-12-31	Operating cash flow	-147180000	Operating Cash Flow: -147180000 Open source
20222022-12-31	Operating cash flow	-224401000	Operating Cash Flow: -224401000 Open source
20232023-12-31	Operating cash flow	-350572000	Operating Cash Flow: -350572000 Open source
20242024-12-31	Operating cash flow	-557436000	Operating Cash Flow: -557436000 Open source
20252025-12-31	Operating cash flow	-897741000	Operating Cash Flow: -897741000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -913.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-286000	Operating Cash Flow: 1213000 Open source Capital Expenditure: 1499000 Open source
20192019-12-31	Free cash flow	-52205000	Operating Cash Flow: -49616000 Open source Capital Expenditure: 2589000 Open source
20202020-12-31	Free cash flow	-102997000	Operating Cash Flow: -100064000 Open source Capital Expenditure: 2933000 Open source
20212021-12-31	Free cash flow	-153708000	Operating Cash Flow: -147180000 Open source Capital Expenditure: 6528000 Open source
20222022-12-31	Free cash flow	-235217000	Operating Cash Flow: -224401000 Open source Capital Expenditure: 10816000 Open source
20232023-12-31	Free cash flow	-358301000	Operating Cash Flow: -350572000 Open source Capital Expenditure: 7729000 Open source
20242024-12-31	Free cash flow	-567744000	Operating Cash Flow: -557436000 Open source Capital Expenditure: 10308000 Open source
20252025-12-31	Free cash flow	-913731000	Operating Cash Flow: -897741000 Open source Capital Expenditure: 15990000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

30.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Liabilities / assets	Not reported	No source recorded
20192019-12-31	Liabilities / assets	30.8%	Total Liabilities: 67994000 Open source Total Assets: 220529000 Open source
20202020-12-31	Liabilities / assets	16.3%	Total Liabilities: 92725000 Open source Total Assets: 567401000 Open source
20212021-12-31	Liabilities / assets	18.3%	Total Liabilities: 135420000 Open source Total Assets: 737988000 Open source
20222022-12-31	Liabilities / assets	15.6%	Total Liabilities: 126742000 Open source Total Assets: 811930000 Open source
20232023-12-31	Liabilities / assets	11.4%	Total Liabilities: 235511000 Open source Total Assets: 2061705000 Open source
20242024-12-31	Liabilities / assets	11.5%	Total Liabilities: 293097000 Open source Total Assets: 2558301000 Open source
20252025-12-31	Liabilities / assets	30.7%	Total Liabilities: 723211000 Open source Total Assets: 2354508000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.14× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Current assets / current liabilities	Not reported	No source recorded
20192019-12-31	Current assets / current liabilities	3.11×	Current Assets: 133981000 Open source Current Liabilities: 43052000 Open source
20202020-12-31	Current assets / current liabilities	9.63×	Current Assets: 454122000 Open source Current Liabilities: 47176000 Open source
20212021-12-31	Current assets / current liabilities	9.77×	Current Assets: 589773000 Open source Current Liabilities: 60350000 Open source
20222022-12-31	Current assets / current liabilities	10.65×	Current Assets: 660185000 Open source Current Liabilities: 61984000 Open source
20232023-12-31	Current assets / current liabilities	13.06×	Current Assets: 1879281000 Open source Current Liabilities: 143851000 Open source
20242024-12-31	Current assets / current liabilities	14.2×	Current Assets: 2327632000 Open source Current Liabilities: 163914000 Open source
20252025-12-31	Current assets / current liabilities	7.14×	Current Assets: 2075037000 Open source Current Liabilities: 290424000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 41.79 million Exact value Exact value: -41789000 USD 2018-01-01 – 2018-12-31: -41789000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Revolution Medicines, Inc. · 2018-12-31 Revolution Medicines, Inc. (edgar:1628171) Net Income: -41789000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41789000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000156459021010276/rvmd-20201231.xml#204560 Filing: 000156459021010276 The citation records this snapshot. The page link may show a newer release later.	USD 1.21 million Exact value Exact value: 1213000 USD 2018-01-01 – 2018-12-31: 1213000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Revolution Medicines, Inc. · 2018-12-31 Revolution Medicines, Inc. (edgar:1628171) Operating Cash Flow: 1213000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1213000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000156459021010276/rvmd-20201231.xml#243927 Filing: 000156459021010276 The citation records this snapshot. The page link may show a newer release later.	USD 1.5 million Exact value Exact value: 1499000 USD 2018-01-01 – 2018-12-31: 1499000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Revolution Medicines, Inc. · 2018-12-31 Revolution Medicines, Inc. (edgar:1628171) Capital Expenditure: 1499000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1499000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000156459021010276/rvmd-20201231.xml#245765 Filing: 000156459021010276 The citation records this snapshot. The page link may show a newer release later.	−USD 286,000 Calculation and evidence 1213000 − 1499000 USD Exact free cash flow: -286000 USD 2018-01-01 – 2018-12-31: 1213000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1499000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Revolution Medicines, Inc. · 2018-12-31 Revolution Medicines, Inc. (edgar:1628171) Free cash flow: -286000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1213000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000156459021010276/rvmd-20201231.xml#243927 Filing: 000156459021010276 Input fundies:CapitalExpenditure: 1499000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000156459021010276/rvmd-20201231.xml#245765 Filing: 000156459021010276 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 47.66 million Exact value Exact value: -47664000 USD 2019-01-01 – 2019-12-31: -47664000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Revolution Medicines, Inc. · 2019-12-31 Revolution Medicines, Inc. (edgar:1628171) Net Income: -47664000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -47664000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017022002297/rvmd-20211231.htm#3978102 Filing: 000095017022002297 The citation records this snapshot. The page link may show a newer release later.	−USD 49.62 million Exact value Exact value: -49616000 USD 2019-01-01 – 2019-12-31: -49616000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Revolution Medicines, Inc. · 2019-12-31 Revolution Medicines, Inc. (edgar:1628171) Operating Cash Flow: -49616000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49616000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017022002297/rvmd-20211231.htm#2531514 Filing: 000095017022002297 The citation records this snapshot. The page link may show a newer release later.	USD 2.59 million Exact value Exact value: 2589000 USD 2019-01-01 – 2019-12-31: 2589000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Revolution Medicines, Inc. · 2019-12-31 Revolution Medicines, Inc. (edgar:1628171) Capital Expenditure: 2589000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2589000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017022002297/rvmd-20211231.htm#2559570 Filing: 000095017022002297 The citation records this snapshot. The page link may show a newer release later.	−USD 52.21 million Calculation and evidence -49616000 − 2589000 USD Exact free cash flow: -52205000 USD 2019-01-01 – 2019-12-31: -49616000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2589000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Revolution Medicines, Inc. · 2019-12-31 Revolution Medicines, Inc. (edgar:1628171) Free cash flow: -52205000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49616000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017022002297/rvmd-20211231.htm#2531514 Filing: 000095017022002297 Input fundies:CapitalExpenditure: 2589000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017022002297/rvmd-20211231.htm#2559570 Filing: 000095017022002297 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 108.16 million Exact value Exact value: -108159000 USD 2020-01-01 – 2020-12-31: -108159000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Revolution Medicines, Inc. · 2020-12-31 Revolution Medicines, Inc. (edgar:1628171) Net Income: -108159000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -108159000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017023004645/rvmd-20221231.htm#4256153 Filing: 000095017023004645 The citation records this snapshot. The page link may show a newer release later.	−USD 100.06 million Exact value Exact value: -100064000 USD 2020-01-01 – 2020-12-31: -100064000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Revolution Medicines, Inc. · 2020-12-31 Revolution Medicines, Inc. (edgar:1628171) Operating Cash Flow: -100064000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -100064000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017023004645/rvmd-20221231.htm#2744767 Filing: 000095017023004645 The citation records this snapshot. The page link may show a newer release later.	USD 2.93 million Exact value Exact value: 2933000 USD 2020-01-01 – 2020-12-31: 2933000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Revolution Medicines, Inc. · 2020-12-31 Revolution Medicines, Inc. (edgar:1628171) Capital Expenditure: 2933000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2933000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017023004645/rvmd-20221231.htm#2776128 Filing: 000095017023004645 The citation records this snapshot. The page link may show a newer release later.	−USD 103 million Calculation and evidence -100064000 − 2933000 USD Exact free cash flow: -102997000 USD 2020-01-01 – 2020-12-31: -100064000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2933000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Revolution Medicines, Inc. · 2020-12-31 Revolution Medicines, Inc. (edgar:1628171) Free cash flow: -102997000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -100064000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017023004645/rvmd-20221231.htm#2744767 Filing: 000095017023004645 Input fundies:CapitalExpenditure: 2933000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017023004645/rvmd-20221231.htm#2776128 Filing: 000095017023004645 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 187.09 million Exact value Exact value: -187091000 USD 2021-01-01 – 2021-12-31: -187091000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Revolution Medicines, Inc. · 2021-12-31 Revolution Medicines, Inc. (edgar:1628171) Net Income: -187091000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -187091000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017024020145/rvmd-20231231.htm#1923875 Filing: 000095017024020145 The citation records this snapshot. The page link may show a newer release later.	−USD 147.18 million Exact value Exact value: -147180000 USD 2021-01-01 – 2021-12-31: -147180000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Revolution Medicines, Inc. · 2021-12-31 Revolution Medicines, Inc. (edgar:1628171) Operating Cash Flow: -147180000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -147180000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017024020145/rvmd-20231231.htm#2178401 Filing: 000095017024020145 The citation records this snapshot. The page link may show a newer release later.	USD 6.53 million Exact value Exact value: 6528000 USD 2021-01-01 – 2021-12-31: 6528000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Revolution Medicines, Inc. · 2021-12-31 Revolution Medicines, Inc. (edgar:1628171) Capital Expenditure: 6528000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6528000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017024020145/rvmd-20231231.htm#2198094 Filing: 000095017024020145 The citation records this snapshot. The page link may show a newer release later.	−USD 153.71 million Calculation and evidence -147180000 − 6528000 USD Exact free cash flow: -153708000 USD 2021-01-01 – 2021-12-31: -147180000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 6528000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Revolution Medicines, Inc. · 2021-12-31 Revolution Medicines, Inc. (edgar:1628171) Free cash flow: -153708000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -147180000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017024020145/rvmd-20231231.htm#2178401 Filing: 000095017024020145 Input fundies:CapitalExpenditure: 6528000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017024020145/rvmd-20231231.htm#2198094 Filing: 000095017024020145 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 248.71 million Exact value Exact value: -248705000 USD 2022-01-01 – 2022-12-31: -248705000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Revolution Medicines, Inc. · 2022-12-31 Revolution Medicines, Inc. (edgar:1628171) Net Income: -248705000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -248705000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017025027736/rvmd-20241231.htm#4010814 Filing: 000095017025027736 The citation records this snapshot. The page link may show a newer release later.	−USD 224.4 million Exact value Exact value: -224401000 USD 2022-01-01 – 2022-12-31: -224401000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Revolution Medicines, Inc. · 2022-12-31 Revolution Medicines, Inc. (edgar:1628171) Operating Cash Flow: -224401000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -224401000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017025027736/rvmd-20241231.htm#2544401 Filing: 000095017025027736 The citation records this snapshot. The page link may show a newer release later.	USD 10.82 million Exact value Exact value: 10816000 USD 2022-01-01 – 2022-12-31: 10816000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Revolution Medicines, Inc. · 2022-12-31 Revolution Medicines, Inc. (edgar:1628171) Capital Expenditure: 10816000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10816000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017025027736/rvmd-20241231.htm#2563951 Filing: 000095017025027736 The citation records this snapshot. The page link may show a newer release later.	−USD 235.22 million Calculation and evidence -224401000 − 10816000 USD Exact free cash flow: -235217000 USD 2022-01-01 – 2022-12-31: -224401000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 10816000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Revolution Medicines, Inc. · 2022-12-31 Revolution Medicines, Inc. (edgar:1628171) Free cash flow: -235217000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -224401000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017025027736/rvmd-20241231.htm#2544401 Filing: 000095017025027736 Input fundies:CapitalExpenditure: 10816000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000095017025027736/rvmd-20241231.htm#2563951 Filing: 000095017025027736 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 436.37 million Exact value Exact value: -436367000 USD 2023-01-01 – 2023-12-31: -436367000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Revolution Medicines, Inc. · 2023-12-31 Revolution Medicines, Inc. (edgar:1628171) Net Income: -436367000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -436367000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#1891610 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	−USD 350.57 million Exact value Exact value: -350572000 USD 2023-01-01 – 2023-12-31: -350572000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Revolution Medicines, Inc. · 2023-12-31 Revolution Medicines, Inc. (edgar:1628171) Operating Cash Flow: -350572000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -350572000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2228881 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	USD 7.73 million Exact value Exact value: 7729000 USD 2023-01-01 – 2023-12-31: 7729000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Revolution Medicines, Inc. · 2023-12-31 Revolution Medicines, Inc. (edgar:1628171) Capital Expenditure: 7729000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7729000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2255121 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	−USD 358.3 million Calculation and evidence -350572000 − 7729000 USD Exact free cash flow: -358301000 USD 2023-01-01 – 2023-12-31: -350572000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 7729000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Revolution Medicines, Inc. · 2023-12-31 Revolution Medicines, Inc. (edgar:1628171) Free cash flow: -358301000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -350572000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2228881 Filing: 000119312526071563 Input fundies:CapitalExpenditure: 7729000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2255121 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 600.09 million Exact value Exact value: -600093000 USD 2024-01-01 – 2024-12-31: -600093000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Revolution Medicines, Inc. · 2024-12-31 Revolution Medicines, Inc. (edgar:1628171) Net Income: -600093000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -600093000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#1988974 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	−USD 557.44 million Exact value Exact value: -557436000 USD 2024-01-01 – 2024-12-31: -557436000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Revolution Medicines, Inc. · 2024-12-31 Revolution Medicines, Inc. (edgar:1628171) Operating Cash Flow: -557436000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -557436000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2227000 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	USD 10.31 million Exact value Exact value: 10308000 USD 2024-01-01 – 2024-12-31: 10308000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Revolution Medicines, Inc. · 2024-12-31 Revolution Medicines, Inc. (edgar:1628171) Capital Expenditure: 10308000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10308000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2253250 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	−USD 567.74 million Calculation and evidence -557436000 − 10308000 USD Exact free cash flow: -567744000 USD 2024-01-01 – 2024-12-31: -557436000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 10308000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Revolution Medicines, Inc. · 2024-12-31 Revolution Medicines, Inc. (edgar:1628171) Free cash flow: -567744000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -557436000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2227000 Filing: 000119312526071563 Input fundies:CapitalExpenditure: 10308000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2253250 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 1.13 billion Exact value Exact value: -1131301000 USD 2025-01-01 – 2025-12-31: -1131301000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Revolution Medicines, Inc. · 2025-12-31 Revolution Medicines, Inc. (edgar:1628171) Net Income: -1131301000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1131301000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2085793 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	−USD 897.74 million Exact value Exact value: -897741000 USD 2025-01-01 – 2025-12-31: -897741000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Revolution Medicines, Inc. · 2025-12-31 Revolution Medicines, Inc. (edgar:1628171) Operating Cash Flow: -897741000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -897741000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2225116 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	USD 15.99 million Exact value Exact value: 15990000 USD 2025-01-01 – 2025-12-31: 15990000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Revolution Medicines, Inc. · 2025-12-31 Revolution Medicines, Inc. (edgar:1628171) Capital Expenditure: 15990000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15990000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2251376 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.	−USD 913.73 million Calculation and evidence -897741000 − 15990000 USD Exact free cash flow: -913731000 USD 2025-01-01 – 2025-12-31: -897741000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 15990000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Revolution Medicines, Inc. · 2025-12-31 Revolution Medicines, Inc. (edgar:1628171) Free cash flow: -913731000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628171?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -897741000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2225116 Filing: 000119312526071563 Input fundies:CapitalExpenditure: 15990000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/rvmd-20251231.htm#2251376 Filing: 000119312526071563 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

33 filings · 2,048 latest values · 2,048 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001628171, 1628171, RVMD, edgar:1628171

Also known as Revolution Medicines, Inc.

Revolution Medicines, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation